<DOC>
	<DOCNO>NCT00709020</DOCNO>
	<brief_summary>RATIONALE : White button mushroom extract may stop delay recurrence breast cancer postmenopausal breast cancer survivor . PURPOSE : This phase I trial study side effect best dose white button mushroom extract prevent recurrence breast cancer postmenopausal woman breast cancer survivor .</brief_summary>
	<brief_title>White Button Mushroom Extract Preventing Recurrence Breast Cancer Postmenopausal Breast Cancer Survivors</brief_title>
	<detailed_description>OBJECTIVES : Primary - To show whole food extract white button mushroom ( WBM ) inhibit aromatase-induced estrogen biosynthesis postmenopausal woman breast cancer survivor ( BCS ) . - To determine optimal daily dose WBM need induce aromatase inhibition estrogen biosynthesis patient . - To determine bioavailability C-18 unsaturated fatty acid , think moderate anticancer effect WBM . Secondary - To determine safety tolerability WBM humans via serial comprehensive symptom questionnaire , pre- post-treatment marker bone metabolism , pre- post-treatment comprehensive lipid panel . - To explore potential alternate antitumor mechanism , specifically effect WBM cytokine well innate adaptive cellular immunity . - To describe barrier experienced recruitment ethnically diverse subject community secondary prevention BCS trial utilize dietary supplement intervention effort enhance feasibility subsequent phase II trial . OUTLINE : This dose-escalation study . Patients receive oral white button mushroom extract twice daily 12 week absence second primary ductal carcinoma situ , invasive breast cancer , unacceptable toxicity . Patients undergo blood urine sample collection baseline periodically treatment pharmacokinetic , pharmacodynamic , immunologic correlative study . Blood urine sample analyze concentration C-18 unsaturated fatty acid ( CUFA ) high-performance liquid chromatography tandem-mass spectrometry . Blood sample also analyze anti-aromatase activity ex vivo plasma aromatase inhibition assay ; circulate sex steroid hormone radioimmunoassay ; serum immune cytokine level multiplex cytokine analysis ; immunophenotyping , NK-cell activation status , NK-cell function multiparameter flow cytometry ; lipid level lipid assay ; biochemical marker bone metabolism bone metabolism marker assay . DNA , RNA , plasma sample store post-trial pharmacogenomic study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Meets 1 follow criterion : Prior diagnosis infiltrate carcinoma breast ≥ 5 year prior study entry Prior diagnosis ductal carcinoma situ No evidence disease Completed cancer therapy , exception reconstructive surgery , least 6 month prior study entry Meets one follow criterion : Normal mammogram within 1 year study entry Underwent bilateral mastectomy remission 5 year , document oncologist Hormone receptor status specify PATIENT CHARACTERISTICS : ECOG performance status 01 WBC ≥ 3,500/mm³ ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9.0 g/dL Postmenopausal , define follow : Continuous absence menstruation 12+ month Status post bilateral oophorectomy Status post hysterectomy folliclestimulating hormone menopausal range Creatinine ≤ 1.5 time upper limit normal ( ULN ) less Total bilirubin ≤ 1.5 time ULN AST ALT &lt; 2 time ULN No allergy mushroom No personal history invasive cancer , breast cancer , squamous cell basal cell skin cancer No osteoporosis , define bonemineral density Tscore &lt; 2.5 dualenergy xray absorptiometry scan No major systemic infection major medical illness cardiovascular , respiratory , digestive system PRIOR CONCURRENT THERAPY : See Disease Characteristics More 3 month since prior concurrent hormonemodifying medication , include follow : Oral contraceptive Hormone replacement Selective estrogen receptor modifier Other aromatase inhibitor Gonadotropicreleasing hormone modifier At least 1 month since prior concurrent mushroom extract DHEA dietary supplement No concurrent therapy , except continued medication unrelated illness exclude , necessary medication unrelated acute illness may occur study ( e.g. , cold , flu , infection ) No 3 concurrent serving per week follow food : Flaxseeds flaxseed meal Highenergy bar diet bar contain soy soy protein Liquidnutrition drink contain soy soy protein ( e.g. , Odwalla Future Shake Ensure Plus ) Miso soup Natto Packaged mixed dish soy tofu ( e.g. , lasagna , burrito , stirfry ) Cooked soybean edamame ( i.e. , green soybean ) Roasted soy nut Soymilk , regular lowfat , plain flavor Soy cheese , cheddar , mozzarella , cram cheese , parmesan ( include food make soy cheese ) Soy protein powder ( e.g. , performance bodybuilder powder ) Soy yogurt , type Soy sauce , tamari , teriyaki sauce , Szechuan sauce , hoisin sauce Soy ice cream , tofutti , soy dessert Tempeh , type Tofu , type , include lowfat , flavor , marinate , smoke Tofu soy breakfast sausage , bacon , breakfast meat Tofu soy cold cut , hot dog , deli meat substitute Veggie soy tofu burger , ground meat substitute ( texturized vegetable protein ) , soy tofu , chicken , turkey Concurrent supplemental calcium and/or vitamin D bisphosphonates allow provided dos remain constant throughout runin treatment portion trial</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>cancer survivor</keyword>
	<keyword>breast cancer</keyword>
</DOC>